^
Association details:
| Biomarker: | CD19 positive |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | azercabtagene zapreleucel (PBCAR0191) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic ‘Off-the-Shelf’ CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL
Published date:
11/04/2021
Excerpt:
Subjects were 18 years or older with CD19+ R/R B-ALL after at least 2 prior lines of therapy...PBCAR0191 has demonstrated a manageable safety profile and high complete response rate at day 28 or later...
DOI:
10.1182/blood-2021-153166
